Month: February 2019


AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for

Shots:  AbCellera to receive technology access fee, milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders On 12 Jun,2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases  AbCellera’s single-cell screening technology is a […]Read More


Novartis Signs a Research Agreement with Target PharmaSolutions for Conducting

Shots: Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs) The initial focus of the collaboration is to develop therapies & expand Novartis’ footprints in immune-dermatology for atopic dermatitis (eczema) with further expansion to hidradenitis suppurativa (painful bumps under the skin), […]Read More


Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for

Shots: Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive […]Read More

MedTech Regulatory

Medtronic Resolute Drug-Eluting Stent (DES) Platform Receives FDA’s Approval for

Shots: The expanded indication approval is based on PERSPECTIVE Study assessing 183 patients with older-generation Resolute Integrity DES The study resulted in low rates of repeat revascularization 1.1%, cardiac death 2.2%, minimal stent thrombosis 0.06% and safe results Resolute Drug-Eluting Stent (DES) platform includes Resolute Onyx and Resolute Integrity DES targeted for the treatment of […]Read More


Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress

Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders The focus of the agreement is to develop non-opioid therapies with advancement […]Read More


Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab)

Shots: The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors In H2’19, companies plan for the onset of the trial based on ACTolog IMA101-101 study protocol at MD Anderson Cancer Center to kill cancer cells by blocking […]Read More